Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain's ability to compensate for damage due to trauma or disease. The Company's PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone215-944-6100
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees10
OptionableNot Optionable
Helius Medical Technologies (OTCMKTS:HSDT) Frequently Asked Questions
What is Helius Medical Technologies' stock symbol?
Helius Medical Technologies trades on the OTCMKTS under the ticker symbol "HSDT."
How were Helius Medical Technologies' earnings last quarter?
Helius Medical Technologies Inc (OTCMKTS:HSDT) released its quarterly earnings results on Thursday, November, 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.04. View Helius Medical Technologies' Earnings History.
What price target have analysts set for HSDT?
1 Wall Street analysts have issued 12-month target prices for Helius Medical Technologies' shares. Their predictions range from $14.00 to $14.00. On average, they anticipate Helius Medical Technologies' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 67.7% from the stock's current price. View Analyst Price Targets for Helius Medical Technologies.
What is the consensus analysts' recommendation for Helius Medical Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Helius Medical Technologies.
Has Helius Medical Technologies been receiving favorable news coverage?
Media headlines about HSDT stock have trended negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Helius Medical Technologies earned a news sentiment score of -2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near future.
Who are some of Helius Medical Technologies' key competitors?
Some companies that are related to Helius Medical Technologies include Medtronic (MDT), Varian Medical Systems (VAR), SONOVA HLDG AG/ADR (SONVY), Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), CONMED (CNMD), Natus Medical (BABY), Viewray (VRAY), AxoGen (AXGN), Semler Scientific (SMLR), BioLife Solutions (BLFS), Cutera (CUTR) and Rockwell Medical (RMTI).
Who are Helius Medical Technologies' key executives?
Helius Medical Technologies' management team includes the folowing people:
- Philippe Deschamps, President, Chief Executive Officer, Director
- Joyce N. LaViscount, Chief Financial Officer, Chief Operating Officer
- Brian Bapty, Vice President, Strategy and Business Development
- Jonathan Sackier, Chief Medical Officer
- Dane Andreeff, Director
- Huaizheng Peng, Director
- Mitch Eugene Tyler, Director
- Thomas E. Griffin, Independent Director
- Edward M. Straw, Independent Director
How do I buy shares of Helius Medical Technologies?
Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Helius Medical Technologies' stock price today?
One share of HSDT stock can currently be purchased for approximately $8.35.
What is Helius Medical Technologies' official website?
How can I contact Helius Medical Technologies?
Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at 215-944-6100 or via email at [email protected]
MarketBeat Community Rating for Helius Medical Technologies (OTCMKTS HSDT)
MarketBeat's community ratings are surveys of what our community members think about Helius Medical Technologies and other stocks. Vote "Outperform" if you believe HSDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
